Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia

Internal Medicine

Volumn 47, Issue 1, 2008, Pages 15-20

  Enomoto, Tatsuji ^a,b   Azuma, Arata ^b   Matsumoto, Aki ^b   Nei, Takahito ^b   Fujita, Kazue ^b   Hattori, Kumiko ^a,b   Saito, Yoshinobu ^b   Abe, Shinji ^b   Usuki, Jiro ^b   Kodoh, Shoji ^b  

^a TOKYO METROPOLITAN HIROO HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Beta glucan; Circulating CD4+ lymphocyte count; Interstitial pneumonia; Pneumocystis pneumonia; Prophylaxis with trimethoprim sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG RESPONSE; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INTERSTITIAL PNEUMONIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SPUTUM EXAMINATION; STEROID THERAPY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; CD4 LYMPHOCYTE COUNT; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PREDNISOLONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 38349011587     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0402     Document Type: Article

References (17)

1. American Thoracic Society and European Respiratory Society: Idiopathic pulmonary fibrosis: diagnosis and treatment: International concensus statement. Am J Respir Crit Care Med 161: 646-664, 2000.
2. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119: 1198-1208, 1993.
3. Hashimoto H, Kanai M. Side effects of glucocorticosteroids. Jpn J Clin Exp Med 81: 798-802, 2004.
4. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Diss 11: 954-963, 1989.
5. Wakefield AE, Pixley FJ, Banerji S, et al. Detection of Pneumocystis carinii with DNA amplification. Lancet 336: 451-453, 1990.
6. Takabayashi K, Kurasawa K, Yamazaki S, et al. Pulmonary opportunistic infections in patients with autoimmune disease. J Jpn Soc Intern Med 78: 1293-1298, 1989 (in Japanese).
7. Stringer JR, Beard CB, Miller RF, et al. A new name (Pneumocystis jiroveci) for pneumocystis from humans. Emerg Infect Dis 8: 891-896, 2002.
8. Beck JM, Warnock ML, Curtis JL, et al. Inflammatory responses to pneumocystis carinii in mice selectively depleted of helper T lymphocyte. Am J Respir Cell Mol Biol 5: 186-197, 1991.
9. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 111: 223-231, 1989.
10. Gluck T, Geerdes-Fenge HF, Straub RH, et al. Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 28: 227-230, 2000.
11. The Committee for Japanese Respiratory Society guideline in the management of respiratory infection, Pneumonia in immunosuppressed patients. The Japanese Respiratory Society Guidelines for Management of Hospital-acquired Pneumonia. The Japanese Respiratory Society, Tokyo, 35-40, 2002 (in Japanese).
12. Saito K, Nakayamada S, Nakano K, et al. Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases. Rheumatology 43: 479-485, 2004.
13. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 297: 1419-1426, 1977.
14. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: more patients, same risk. Arch Intern Med 155: 1125-1128, 1995.
15. Sepkowitz KA. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? Mayo Clin Proc 71: 102-103, 1996.
16. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1→3) beta-D-Glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 3: 197-199, 1996.
17. Okamoto K, Yamamoto T, Nonaka D, et al. Plasma (1→3)-beta-D-glucan measurement and polymerase chain reaction on sputum as practical parameters in Pneumocystis carinii pneumonia. Intern Med 37: 618-621, 1998.